New radioactive drug aims to halt bone metastases in advanced cancers
NCT ID NCT07249892
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial tests a new drug called BPR-6023021, which is a radioactive compound designed to target bone. It is for people with advanced solid tumors that have spread to the bone and who have no other standard treatment options. The study will enroll 195 participants to evaluate the drug's safety, how it moves through the body, and whether it can slow bone tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BPR-6023021 (a radioactive drug that targets bone)
- What this could lead to
- If it works, this could provide a new treatment option to control bone metastases and delay disease progression in advanced solid tumors.
- What could go wrong
- This is an early-phase trial (Phase I/II) with only 195 participants, so safety and effectiveness are not yet proven. The drug is radioactive, which carries risks of side effects like bone marrow suppression or organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR WITH BONE METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can your own immune cells fight advanced cancer?
- Can a radioactive antibody light up hidden cancers on PET scans?
- Blood test may let cancer patients take safe breaks from immunotherapy
- Off-the-Shelf cell therapy takes on Hard-to-Treat cancers
- New drug duo aims to reboot immune attack on Hard-to-Treat cancers